文献速递帕金森病与运动障碍认知障碍与痴呆

帕金森病肠道微生物生态系统:多组学的新临床生物学见解

Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi-Omics.
PubMed 文献 · Ann Neurol · 2021-01-11

帕金森病患者粪便微生物组和代谢组组成与对照显著不同,核磁共振代谢组效应量最大,且差异在全面混杂因素分析后仍显著。低短链脂肪酸与较差认知和低体重指数显著相关,丁酸盐水平较低与更差姿势不稳-步态障碍评分相关。

要点

  • 帕金森病患者粪便微生物组和代谢组组成与对照显著不同。
  • 低短链脂肪酸与较差认知和低体重指数显著相关。
  • 较低丁酸盐水平与更差姿势不稳-步态障碍评分相关。

核心结论

  • 帕金森病患者肠道微生物功能改变,表现为差异丰富的代谢特征,为肠-脑病理生理学提供重要生物学见解。
  • 微生物代谢物的临床相关性支持其作为帕金森病新生物标志物和治疗开发靶点的潜力。

研究设计与样本

  • 粪便样本采用16S rRNA基因测序分析微生物组。
  • 粪便代谢组学采用核磁共振波谱和液相色谱-质谱两个平台分析。

主要发现

  • 帕金森病患者粪便微生物组和代谢组组成与对照显著不同,核磁共振代谢组效应量最大。
  • 微生物组和核磁共振代谢组组成差异在全面混杂因素分析后仍显著。
  • 差异丰富的粪便代谢物特征和预测功能变化包括短链脂肪酸、泛醌和水杨酸盐等潜在神经保护分子,以及神经酰胺、鞘氨醇和三甲胺N-氧化物等与神经退行性变相关化合物。
  • 帕金森病组中,认知障碍、低体重指数、衰弱、便秘和低体力活动与粪便代谢组组成差异相关。
  • 帕金森病患者低短链脂肪酸与较差认知和低体重指数显著相关,较低丁酸盐水平与更差姿势不稳-步态障碍评分相关。

临床怎么用

  • 粪便代谢组学可提供微生物活性的功能读出,辅助评估帕金森病患者肠道微生物功能改变。
  • 低短链脂肪酸和丁酸盐水平与认知、体重指数及姿势不稳-步态障碍相关,提示微生物代谢物可能作为临床相关标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gut microbiome alterations in Parkinson disease (PD) have been reported repeatedly, but their functional relevance remains unclear. Fecal metabolomics, which provide a functional readout of microbial activity, have scarcely been investigated. We investigated fecal microbiome and metabolome alterations in PD, and their clinical relevance. METHODS: Two hundred subjects (104 patients, 96 controls) underwent extensive clinical phenotyping. Stool samples were analyzed using 16S rRNA gene sequencing. Fecal metabolomics were performed using two platforms, nuclear magnetic resonance (NMR) spectroscopy and liquid chromatography-mass spectrometry. RESULTS: Fecal microbiome and metabolome composition in PD was significantly different from controls, with the largest effect size seen in NMR-based metabolome. Microbiome and NMR-based metabolome compositional differences remained significant after comprehensive confounder analyses. Differentially abundant fecal metabolite features and predicted functional changes in PD versus controls included bioactive molecules with putative neuroprotective effects (eg, short chain fatty acids [SCFAs], ubiquinones, and salicylate) and other compounds increasingly implicated in neurodegeneration (eg, ceramides, sphingosine, and trimethylamine N-oxide). In the PD group, cognitive impairment, low body mass index (BMI), frailty, constipation, and low physical activity were associated with fecal metabolome compositional differences. Notably, low SCFAs in PD were significantly associated with poorer cognition and low BMI. Lower butyrate levels correlated with worse postural instability-gait disorder scores. INTERPRETATION: Gut microbial function is altered in PD, characterized by differentially abundant metabolic features that provide important biological insights into gut-brain pathophysiology. Their clinical relevance further supports a role for microbial metabolites as potential targets for the development of new biomarkers and therapies in PD. ANN NEUROL 2021;89:546-559.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Tan AH, Chong CW, Lim SY, et al. Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi-Omics. Ann Neurol. 2021. PMID: 33274480. doi:10.1002/ana.25982

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。